National Institute for Health and Clinical Excellence (NICE)
NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation
NICE yesterday (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).
The updated guideline addresses several areas where new evidence has become available since publication of the previous guideline in 2014. These include the use of tools to calculate the risk of bleeding when considering the use of anti-clotting drugs (anticoagulants), the role of newer anti-clotting drugs, and the use of treatments that aim to destroy or isolate the abnormal sources of electrical impulses in the heart that may be driving AF (ablation).
Accurate knowledge of bleeding risk supports shared decision making and has practical benefits (for example, increasing a person’s confidence and willingness to have anti-clotting treatment when risk is low and prompting a discussion of how to reduce the risk of bleeding when risk is high). Evidence shows that a tool called ORBIT is the most accurate one for predicting the risk of bleeding in people with AF. However, the guideline acknowledges that other bleeding risk tools, including HAS-BLED which NICE’s previous guideline recommended, may need to be used until ORBIT is embedded in clinical pathways and electronic systems used by clinicians.
The guideline recommends that anticoagulation with drugs called direct-acting oral anticoagulants should be offered to people with atrial fibrillation who have a high risk of stroke, taking into account the risk of bleeding. For men with a moderate risk of stroke, the guideline recommends that anticoagulation with a direct-acting oral anticoagulant should be considered. Apixaban, dabigatran, edoxaban and rivaroxaban are all recommended as options, when used in line with the criteria specified in the relevant NICE technology appraisal guidance.
A vitamin K antagonist (for example warfarin) is recommended as an alternative if direct-acting oral anticoagulants are contraindicated, not tolerated or not suitable.
When drug treatment is unsuccessful, unsuitable or not tolerated in people with symptomatic intermittent or persistent atrial fibrillation the updated guideline says radiofrequency point-by-point ablation (which uses heat energy to precisely disable heart tissue that causes irregular heartbeats) should be considered or, if this isn’t suitable, either cryoballoon ablation (a type of ablation which uses freezing energy rather than heat) or laser balloon ablation (which uses catheters inside the heart to ablate tissue using a laser guided by a camera) can be considered.
Atrial fibrillation is the most common heart rhythm disorder (affecting approximately 2% of the adult population), and estimates suggest its prevalence is increasing. Atrial fibrillation causes palpitations and breathlessness in many people but it may be silent and undetected. If left untreated it is a significant risk factor for stroke and other morbidities: it is estimated that it is responsible for approximately 20% of all strokes and is associated with increased mortality. Men are more commonly affected than women and the prevalence increases with age and in underlying heart disease, diabetes, obesity and hypertension.
The aim of treatment is to prevent complications, particularly stroke, and alleviate symptoms.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
A refreshed Evidence Standards Framework for Digital Health Technologies and an increased focus on digital health for NICE11/05/2021 14:15:00
Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy07/05/2021 16:15:00
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.
NICE announces more people eligible for nusinersen following review of Managed Access Agreement04/05/2021 14:15:00
NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).
New draft guidance aims to achieve fairer outcomes for looked-after children and young people30/04/2021 16:15:00
Looked after children and young people should be considered ‘one of their own’ by carers, in order to help them to reach their full potential, new NICE draft guidelines say
NICE signs up to join the GetReal Institute29/04/2021 09:15:00
NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.
Thousands with high cholesterol set to benefit from new treatment on the NHS28/04/2021 14:15:00
Thousands of people with high cholesterol will soon have access to a new treatment option on the NHS as a result of final NICE guidance published today (28 April 2021).
NICE recommends new treatment for rare blood disorder23/04/2021 11:15:00
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia21/04/2021 13:05:00
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer21/04/2021 11:15:00
NICE yesterday (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.